Prevalence of Metabolic Syndrome and Associated Factors in a Cohort of Individuals With Treatment-Resistant Depression

Ophelia Godin; Djamila Bennabi; Antoine Yrondi; Raphaëlle Richieri; Thierry D’amato; Franck Bellivier; Thierry Bougerol; Mathilde Horn; Vincent Camus; Philippe Courtet; Olivier Doumy; Jean Baptiste Genty; Wissam El-Hage; Frédéric Haesebaert; Jérôme Holtzmann; Christophe Lançon; Marion Leboyer; Pierre Michel Llorca; Julia Maruani; Fanny Moliere; Ludovic Samalin; Laurent Schmitt; Florian Stéphan; Guillaume Vaiva; Michel Walter; Bruno Aouizerate; Emmanuel Haffen

doi:10.4088/JCP.19m12755

Article dans une revue

Prevalence of Metabolic Syndrome and Associated Factors in a Cohort of Individuals With Treatment-Resistant Depression

Ophelia Godin ^{1, 2} Djamila Bennabi ^{3, 4} Antoine Yrondi ^{5, 2} Raphaëlle Richieri ^{6, 2} Thierry D’amato ^{2, 7} Franck Bellivier ^{8, 9} Thierry Bougerol ^{10, 11} Mathilde Horn ^{12, 2} Vincent Camus ^{13, 2} Philippe Courtet ^{14, 2} Olivier Doumy ^{2, 13} Jean Baptiste Genty ^{2, 15} Wissam El-Hage ^{16, 2} Frédéric Haesebaert ^{2, 7} Jérôme Holtzmann ^{2, 11} Christophe Lançon ^{6, 2} Marion Leboyer ^{8, 15, 2} Pierre Michel Llorca ^{17, 2} Julia Maruani ^{18, 19} Fanny Moliere ^{2, 11} Ludovic Samalin ^{17, 2} Laurent Schmitt ^{20, 2} Florian Stéphan ^{17, 2} Guillaume Vaiva ^{12, 2} Michel Walter ²¹ Bruno Aouizerate ^{22, 2} Emmanuel Haffen ^{23, 2}

1 iPLESP - Institut Pierre Louis d'Epidémiologie et de Santé Publique

2 Fondation FondaMental [Créteil]

3 UBFC - Université Bourgogne Franche-Comté [COMUE]

4 NEURO - Laboratoire de Neurosciences Intégratives et Cliniques - UFC (EA 481)

5 ToNIC - Toulouse Neuro Imaging Center

6 LA CONCEPTION - Hôpital de la Conception [CHU - APHM]

7 Centre Hospitalier le Vinatier [Bron]

8 Neurobiologie et Psychiatrie

9 VariaPsy - U1144 - Optimisation Thérapeutique en Neuropsychopharmacologie

10 GIN - Grenoble Institut des Neurosciences

11 CHU - Centre Hospitalier Universitaire [Grenoble]

12 SCALab - Sciences Cognitives et Sciences Affectives (SCALab) - UMR 9193

13 CHU Trousseau [Tours]

14 CHRU Montpellier - Centre Hospitalier Régional Universitaire [Montpellier]

15 IMRB - Institut Mondor de Recherche Biomédicale

16 iBrain - Inserm U1253 - UNIV Tours - Imagerie et Cerveau

17 NPsy-Sydo - Neuro-Psycho Pharmacologie des Systèmes Dopimanégiques sous-corticaux - Clermont Auvergne

18 UPD5 Médecine - Université Paris Descartes - Faculté de Médecine

19 OPTeN (UMR_S_1144 / U1144) - Optimisation thérapeutique en Neuropsychopharmacologie

20 CHU Toulouse [Toulouse]

21 CHU - BREST - Hopital de Bohars - CHRU Brest

22 CHRU Brest - Centre Hospitalier Régional Universitaire de Brest

23 Hôpital Charles Perrens

Abstract : BACKGROUND: The aim of this study was to estimate the prevalence of metabolic syndrome (MetS) and its components in a cohort of French patients with treatment-resistant depression (TRD) and to determine correlations with sociodemographic, clinical, and treatment-related factors. METHODS: From 2012 to 2018, 205 patients who met DSM-IV criteria for major depressive episode with moderate-to-severe symptoms (Montgomery-Asberg Depression Rating Scale score ≥ 20), and at least Stage II resistance according to Thase and Rush criteria were enrolled in the FondaMental Advanced Centers of Expertise in Resistant Depression (FACE-DR) cohort. Data on sociodemographic and clinical characteristics, lifestyle information, and treatment and comorbidities were collected, and a blood sample was drawn. MetS was defined according to the criteria of the International Diabetes Federation. RESULTS: Overall, 38% of individuals with TRD met criteria for MetS. The frequency of MetS was significantly higher in men than in women only for patients aged 40 years or older (46.3% vs 35.2%, P = .0427). Moreover, whereas the management for diabetes was good, less than one-third of the patients with high blood pressure or dyslipidemia were treated for these conditions. Multivariate analysis showed that individuals with abnormal plasma c-reactive protein levels had a 3-fold increased risk (95% CI, 1.5-5.2) of having MetS, independent of other potential confounders. CONCLUSION: The prevalence of MetS is higher in patients with TRD than in those with other psychiatric disorders and characterized by a considerable undertreatment of some components of MetS in this population. Diagnosis and treatment of the components of MetS should be systematically performed to prevent the occurrence of cardiovascular diseases in patients with TRD. These findings highlight the need for integrated care, with more interaction and coordination between psychiatrists and primary care providers.

Keywords : Prevalence of metabolic syndrome (MetS) Treatment-resistant depression (TRD)

Domaine :

Sciences cognitives

Sciences du Vivant [q-bio] / Médecine humaine et pathologie / Psychiatrie et santé mentale

Liste complète des métadonnées

https://hal.umontpellier.fr/hal-02555531
Contributeur : Nathalie Salvy-Cordoba <>
Soumis le : lundi 27 avril 2020 - 12:49:43
Dernière modification le : vendredi 15 mai 2020 - 12:22:09

Prevalence of Metabolic Syndrome and Associated Factors in a Cohort of Individuals With Treatment-Resistant Depression

Identifiants

Collections

Citation

Exporter

Métriques

30

Prevalence of Metabolic Syndrome and Associated Factors in a Cohort of Individuals With Treatment-Resistant Depression

Identifiants

Collections

Citation

Exporter

Partager

Métriques

30